Lynx Financial

Bone Index Finland Ltd. specializes in osteoporosis diagnostics and has developed Bindex, a device designed for measuring multisite cortical bone thickness. Founded in 2011 and located in Kuopio, Finland, Bone Index offers Bindex as an alternative to conventional DXA devices, adhering to international guidelines for osteoporosis assessment. The device measures the cortical thickness of the tibia, and the results, when combined with additional patient data, can estimate bone mineral density in the hip region. Bindex is particularly beneficial for high-volume screenings of at-risk populations, allowing for the early identification of osteoporosis risk before any fractures occur. This capability not only enhances patient quality of life but also contributes to cost savings in public health care.

Elucida Oncology, Inc. is engaged in developing a nanoparticle drug delivery platform aimed at improving the detection, visualization, and treatment of cancer. The company’s primary technology, the Target/Clear C-Dot platform, utilizes ultra-small cancer-targeting particles that encapsulate a near-infrared dye within a rigid silica shell. This innovative design allows for effective targeting of cancer cells while ensuring rapid clearance from the body through the renal system. Elucida's platform is applicable in various areas, including diagnostic imaging and surgical interventions, as well as in the treatment of primary solid tumors and metastatic cancers. Founded in 2014 and headquartered in Monmouth Junction, New Jersey, Elucida Oncology is focused on enhancing patient outcomes through precision engineering technology that minimizes off-target toxicities and improves the overall safety profile of cancer therapies.

Aurealis Therapeutics is focused on developing innovative solutions for the treatment of non-healing wounds and complex inflammatory diseases. The company is advancing its four-in-one biologic drug, AUP-16, which aims to provide rapid and complete healing, particularly in diabetic foot ulcers. By the end of 2022, Aurealis intends to produce significant Phase 2 clinical efficacy data and non-clinical proof-of-concept data for other inflammatory conditions. In addition to its therapeutic developments, the company's cell and gene therapy platform introduces a novel class of combination immunotherapy that is efficient, scalable, and cost-effective, allowing medical professionals to effectively activate and modulate innate immune systems. Aurealis Therapeutics is actively seeking strategic partnerships to maximize the impact of its groundbreaking technology on patient care.